ClinicalTrials.gg
CompletedNCT04076943Updated Jun 3, 2022Results posted

Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced Anemia

A Phase 2 interventional study of Roxadustat in Chemotherapy Induced Anemia, sponsored by FibroGen. Completed at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-03.

Sponsored by FibroGen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
92
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing roxadustat in Anemia — 2 open to participants now, 4 under way, 3 of them phase 3. roxadustat · Anemia.

Enrollment
30th of 43
92 · median 154
Started
2019
with 1 other
Phase 2
8 of 43
none open now
Registered
28th of 43
by date
Lead sponsor
20 of 43
FibroGen

Among the 43 studies testing roxadustat in Anemia, this one is the 30th largest by enrollment, is one of 2 that started in 2019, is one of 8 in phase 2, and was the 28th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

2 of the 43 studies testing roxadustat in Anemia are open now. Recruiting first, the newest first:

All 2 open studies →

About roxadustat

roxadustat: first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing roxadustat in Anemia, or all of them as a file.
02

Study summary

The purpose of this study is to find out if roxadustat (also known as FG-4592) is safe and effective for the treatment of anemia in participants receiving chemotherapy treatment for cancer.

Read the detailed description

This study consists of three periods:

  1. Screening Period up to 28 days
  2. Treatment Period of up to16 weeks
  3. A Follow-up period of 4 weeks.
03

Conditions studied

  • Chemotherapy Induced Anemia

Browse trials for

Keywords

  • Anemia
  • Chemotherapy induced anemia
  • Myelosuppressive chemotherapy
  • Non-Myeloid malignances
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of non-myeloid
  2. Anemia caused by cancer treatment (myelosuppressive chemotherapy) defined as ≤10.0 grams (g)/deciliter (dL) at screening
  3. Planned concurrent treatment of cancer with chemotherapy for at least 8 additional weeks
  4. Estimated ≥ 6 months at enrollment (Day 1)

Exclusion criteria

Exclusion Criteria:

  1. Participants with cancer receiving chemotherapy when the anticipated outcome is cure
  2. Participants who are only receiving hormonal products, biological products, cancer immunotherapy or radiation therapy to treat/manage their cancer
  3. History of leukemia
  4. Participants who have received an RBC transfusion or erythropoietic therapy within 4 weeks of enrollment
  5. Use of any drug within 8-weeks prior to treatment with roxadustat
  6. anemia due to other etiologies
  7. Cardiovascular risks, such as myocardial infarction, stroke, heart failure or thromboembolic event (for example, deep vein thrombosis [DVT] or pulmonary embolism) within previous 6 months of screening
  8. Clinically significant or uncontrolled ongoing disease (for example, rheumatoid arthritis, Crohn's disease, celiac disease, etc.)
  9. Known (HIV), or infection
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
92 participants (actual)

Study arms

  • Experimental
    Roxadustat

    Participants will receive roxadustat as an oral tablet, 3 times per week (TIW) for up to a maximum of 16 weeks.

    Drug: Roxadustat

Interventions

  • Roxadustat will be administered per schedule specified in the arm description.

    Also known as: FG-4592

06

What researchers measure

Primary outcomes

  1. Maximum Change in Hb Within 16 Weeks From Baseline Without Red Blood Cell (RBC) Transfusion

    Baseline Hb was defined as the mean of the assessments from central lab prior to first dose of the study treatment, which included up to 2 latest screening values prior to Day 1 and a value on Day 1. All central lab assessments from Day 1 to end of treatment (EOT) or early termination (ET) were included in the evaluation of this endpoint. Hb values within 4 weeks after an RBC transfusion were excluded.

    Time frame: Baseline, up to Week 16

Secondary outcomes

  1. Mean Change in Hb Level From Baseline to Week 16 (Without RBC Transfusion)

    Baseline Hb was defined as the mean of the assessments from central lab prior to first dose of the study treatment, which included up to 2 latest screening values prior to Day 1 and a value on Day 1. Mean Hb during treatment was computed using the mean area-under-the-curve trapezoid method, from Day 1 to EOT or ET Hb assessment.

    Time frame: Baseline, Week 16

  2. Change in Hb From Baseline at Weeks 9, 13, and 16 (Without RBC Transfusion)

    Baseline Hb was defined as the mean of the assessments from central lab prior to first dose of the study treatment, which included up to 2 latest screening values prior to Day 1 and a value on Day 1.

    Time frame: Baseline, Weeks 9, 13, and 16

  3. Percentage of Participants Who Achieved a ≥1 g/dL Increase in Hb From Baseline Through Week 16

    The 95% confidence interval (CI) was based on the exact method of Clopper-Pearson method. All central lab assessments from Day 1 to EOT or ET were included in the analysis. Hb values within 4 weeks after an RBC transfusion was excluded.

    Time frame: Baseline through Week 16

  4. Time to Achieve a ≥1 g/dL Increase in Hb From Baseline Through Week 16

    Median was calculated using Kaplan-Meier product limit method. 95% CI was calculated using the method of Brookmeyer and Crowley. All central lab assessments from Day 1 to EOT or ET were included in the analysis. Hb values within 4 weeks after an RBC transfusion were excluded.

    Time frame: Baseline through Week 16

  5. Percentage of Participants Who Achieved a ≥1.5 g/dL Increase in Hb From Baseline Through Week 16

    The 95% CI was based on the exact method of Clopper-Pearson method. All central lab assessments from Day 1 to EOT or ET were included in the analysis. Hb values within 4 weeks after an RBC transfusion was excluded.

    Time frame: Baseline through Week 16

  6. Percentage of Participants Who Achieved a Hematopoietic Response

    Hematopoietic response was defined as an increase in Hb of 1.5 g/dL from baseline or attaining a Hb of 11 g/dL. The 95% CI was based on the exact method of Clopper-Pearson method. All central lab assessments from Day 1 to EOT or ET were included in the analysis. Hb values within 4 weeks after an RBC transfusion was excluded.

    Time frame: Baseline through Week 16

  7. Percentage of Participants Who Achieved a ≥2 g/dL Increase in Hb From Baseline Through Week 16

    The 95% CI was based on the exact method of Clopper-Pearson method. All central lab assessments from Day 1 to EOT or ET were included in the analysis. Hb values within 4 weeks after an RBC transfusion was excluded.

    Time frame: Baseline through Week 16

  8. Percentage of Participants Who Had an RBC Transfusion From Beginning of Week 5 (Day 29) to Week 16

    Time frame: Week 5 to Week 16

07

Results

Posted Jun 3, 2022

Participant flow

Participant flow — Overall Study
MilestoneRoxadustat
Started92
Received at least 1 dose of study drug92
Completed58
Not completed34
Withdrew: Withdrawal by subject12
Withdrew: Adverse event1
Withdrew: Progressive disease2
Withdrew: Death13
Withdrew: Other than specified6

Outcome measures

PrimaryMaximum Change in Hb Within 16 Weeks From Baseline Without Red Blood Cell (RBC) Transfusion

Baseline Hb was defined as the mean of the assessments from central lab prior to first dose of the study treatment, which included up to 2 latest screening values prior to Day 1 and a value on Day 1. All central lab assessments from Day 1 to end of treatment (EOT) or early termination (ET) were included in the evaluation of this endpoint. Hb values within 4 weeks after an RBC transfusion were excluded.

Time frame:
Baseline, up to Week 16
Reported as:
Mean · g/dL
Maximum Change in Hb Within 16 Weeks From Baseline Without Red Blood Cell (RBC) Transfusion
g/dLRoxadustat
Maximum Change in Hb Within 16 Weeks From Baseline Without Red Blood Cell (RBC) Transfusion2.47 ± 1.510
SecondaryMean Change in Hb Level From Baseline to Week 16 (Without RBC Transfusion)

Baseline Hb was defined as the mean of the assessments from central lab prior to first dose of the study treatment, which included up to 2 latest screening values prior to Day 1 and a value on Day 1. Mean Hb during treatment was computed using the mean area-under-the-curve trapezoid method, from Day 1 to EOT or ET Hb assessment.

Time frame:
Baseline, Week 16
Reported as:
Mean · g/dL
Mean Change in Hb Level From Baseline to Week 16 (Without RBC Transfusion)
g/dLRoxadustat
Mean Change in Hb Level From Baseline to Week 16 (Without RBC Transfusion)1.20 ± 1.012
SecondaryChange in Hb From Baseline at Weeks 9, 13, and 16 (Without RBC Transfusion)

Baseline Hb was defined as the mean of the assessments from central lab prior to first dose of the study treatment, which included up to 2 latest screening values prior to Day 1 and a value on Day 1.

Time frame:
Baseline, Weeks 9, 13, and 16
Reported as:
Mean · g/dL
Change in Hb From Baseline at Weeks 9, 13, and 16 (Without RBC Transfusion)
g/dLRoxadustat
Change at Week 91.43 ± 1.421
Change at Week 132.15 ± 1.921
Change at Week 162.52 ± 1.700
SecondaryPercentage of Participants Who Achieved a ≥1 g/dL Increase in Hb From Baseline Through Week 16

The 95% confidence interval (CI) was based on the exact method of Clopper-Pearson method. All central lab assessments from Day 1 to EOT or ET were included in the analysis. Hb values within 4 weeks after an RBC transfusion was excluded.

Time frame:
Baseline through Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a ≥1 g/dL Increase in Hb From Baseline Through Week 16
percentage of participantsRoxadustat
Percentage of Participants Who Achieved a ≥1 g/dL Increase in Hb From Baseline Through Week 1682.0 (72.5 to 89.4)
SecondaryTime to Achieve a ≥1 g/dL Increase in Hb From Baseline Through Week 16

Median was calculated using Kaplan-Meier product limit method. 95% CI was calculated using the method of Brookmeyer and Crowley. All central lab assessments from Day 1 to EOT or ET were included in the analysis. Hb values within 4 weeks after an RBC transfusion were excluded.

Time frame:
Baseline through Week 16
Reported as:
Median · days
Time to Achieve a ≥1 g/dL Increase in Hb From Baseline Through Week 16
daysRoxadustat
Time to Achieve a ≥1 g/dL Increase in Hb From Baseline Through Week 1641.0 (29.0 to 46.0)
SecondaryPercentage of Participants Who Achieved a ≥1.5 g/dL Increase in Hb From Baseline Through Week 16

The 95% CI was based on the exact method of Clopper-Pearson method. All central lab assessments from Day 1 to EOT or ET were included in the analysis. Hb values within 4 weeks after an RBC transfusion was excluded.

Time frame:
Baseline through Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a ≥1.5 g/dL Increase in Hb From Baseline Through Week 16
percentage of participantsRoxadustat
Percentage of Participants Who Achieved a ≥1.5 g/dL Increase in Hb From Baseline Through Week 1673.0 (62.6 to 81.9)
SecondaryPercentage of Participants Who Achieved a Hematopoietic Response

Hematopoietic response was defined as an increase in Hb of 1.5 g/dL from baseline or attaining a Hb of 11 g/dL. The 95% CI was based on the exact method of Clopper-Pearson method. All central lab assessments from Day 1 to EOT or ET were included in the analysis. Hb values within 4 weeks after an RBC transfusion was excluded.

Time frame:
Baseline through Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Hematopoietic Response
percentage of participantsRoxadustat
Percentage of Participants Who Achieved a Hematopoietic Response75.3 (65.0 to 83.8)
SecondaryPercentage of Participants Who Achieved a ≥2 g/dL Increase in Hb From Baseline Through Week 16

The 95% CI was based on the exact method of Clopper-Pearson method. All central lab assessments from Day 1 to EOT or ET were included in the analysis. Hb values within 4 weeks after an RBC transfusion was excluded.

Time frame:
Baseline through Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a ≥2 g/dL Increase in Hb From Baseline Through Week 16
percentage of participantsRoxadustat
Percentage of Participants Who Achieved a ≥2 g/dL Increase in Hb From Baseline Through Week 1660.7 (49.7 to 70.9)
SecondaryPercentage of Participants Who Had an RBC Transfusion From Beginning of Week 5 (Day 29) to Week 16
Time frame:
Week 5 to Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Had an RBC Transfusion From Beginning of Week 5 (Day 29) to Week 16
percentage of participantsRoxadustat
Percentage of Participants Who Had an RBC Transfusion From Beginning of Week 5 (Day 29) to Week 1614.5

Adverse events

Collected over Baseline up to Week 20. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Roxadustat17/92 (18.5%)40/92 (43.5%)71/92 (77.2%)
Most frequent serious events
Showing 10 of 53
Most frequent serious events
EventRoxadustat
Pancreatic carcinoma metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)4/92
Pulmonary embolismRespiratory, thoracic and mediastinal disorders4/92
Febrile neutropeniaBlood and lymphatic system disorders3/92
AstheniaGeneral disorders3/92
Disease progressionGeneral disorders3/92
SepsisInfections and infestations3/92
Mental status changesPsychiatric disorders3/92
Deep vein thrombosisVascular disorders3/92
AnaemiaBlood and lymphatic system disorders3/92
Acute myocardial infarctionCardiac disorders2/92
Most frequent other events
Showing 10 of 23
Most frequent other events
EventRoxadustat
FatigueGeneral disorders23/92
NauseaGastrointestinal disorders18/92
DyspnoeaRespiratory, thoracic and mediastinal disorders16/92
DiarrhoeaGastrointestinal disorders14/92
VomitingGastrointestinal disorders12/92
Deep vein thrombosisVascular disorders11/92
NeutropeniaBlood and lymphatic system disorders10/92
ThrombocytopeniaBlood and lymphatic system disorders10/92
ConstipationGastrointestinal disorders10/92
Decreased appetiteMetabolism and nutrition disorders10/92

Baseline characteristics

Intent-to-treat (ITT) population included all participants enrolled in the roxadustat treatment period and received at least 1 dose of study medication.

Age, Continuous
Age, Continuous(years)Roxadustat
Mean66.8 ± 10.44
Sex: Female, Male
Sex: Female, Male(Participants)Roxadustat
Female53
Male39
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Roxadustat
Hispanic or Latino7
Not Hispanic or Latino82
Unknown or Not Reported3
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Roxadustat
White76
Black or African American12
Asian3
Other1
Baseline Hemoglobin (Hb)
Baseline Hemoglobin (Hb)(grams (g)/deciliter (dL))Roxadustat
Mean8.59 ± 0.956
08

Study locations

15 sites
  • Research Center
    Los Alamitos, California 90720, United States
  • Research Center
    Los Angeles, California 90024, United States
  • Research Center
    Torrance, California 90505, United States
  • Research Center
    Jacksonville, Florida 32256, United States
  • Research Center
    Plantation, Florida 33322, United States
  • Research Center
    Fort Wayne, Indiana 46804, United States
  • Research Center
    Ashland, Kentucky 41101, United States
  • Research Center
    Covington, Louisiana 70433, United States
  • Research Center
    Bethesda, Maryland 20817, United States
  • Research Center
    Livingston, New Jersey 07039, United States
  • Research Center
    Bronx, New York 10469, United States
  • Research Center
    Port Jefferson Station, New York 11776, United States
  • Research Center
    Canton, Ohio 44718, United States
  • Research Center
    Gettysburg, Pennsylvania 17325, United States
  • Research Center
    Philadelphia, Pennsylvania 19106, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2019 to primary completion in Mar 2021, 19 months.

Results were first posted in Jun 2022, 1 year 2 months after primary completion.

Of 58 industry-sponsored phase 2 interventional studies under Anemia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 40. This study's 19 months is below that.

Counting every sponsor, half of 88 studies reached it within 28 months; a quarter within 16 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2019
First posted
Sep 4, 2019
StartActual
Aug 20, 2019
Primary completionActual
Mar 26, 2021
CompletionActual
Apr 23, 2021
Results first posted
Jun 3, 2022
Last update
Jun 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04076943
Lead sponsor
FibroGen
Responsible party
Sponsor
First posted
Sep 4, 2019
Start date
Aug 20, 2019
Primary completion
Mar 26, 2021
Completion
Apr 23, 2021
Results posted
Jun 3, 2022
Last update
Jun 3, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roxadustat

Start the discussion